| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-146 |
Sentence |
denotes |
Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. |
| T1 |
0-146 |
Sentence |
denotes |
Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. |
| TextSentencer_T2 |
147-313 |
Sentence |
denotes |
Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency is a disorder of fatty acid beta oxidation that reportedly has high rates of morbidity and mortality. |
| T2 |
147-313 |
Sentence |
denotes |
Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency is a disorder of fatty acid beta oxidation that reportedly has high rates of morbidity and mortality. |
| TextSentencer_T3 |
314-504 |
Sentence |
denotes |
We describe the outcome of a 5-year-old girl with VLCAD deficiency who was first seen at 5 months of age with severe hypertrophic cardiomyopathy, hepatomegaly, encephalopathy, and hypotonia. |
| T3 |
314-504 |
Sentence |
denotes |
We describe the outcome of a 5-year-old girl with VLCAD deficiency who was first seen at 5 months of age with severe hypertrophic cardiomyopathy, hepatomegaly, encephalopathy, and hypotonia. |
| TextSentencer_T4 |
505-591 |
Sentence |
denotes |
Biochemical studies indicated VLCAD deficiency caused by a stable yet inactive enzyme. |
| T4 |
505-591 |
Sentence |
denotes |
Biochemical studies indicated VLCAD deficiency caused by a stable yet inactive enzyme. |
| TextSentencer_T5 |
592-723 |
Sentence |
denotes |
Molecular genetic analysis of her VLCAD gene revealed a T1372C (F458L) missense mutation and a 1668 ACAG 1669 splice site mutation. |
| T5 |
592-723 |
Sentence |
denotes |
Molecular genetic analysis of her VLCAD gene revealed a T1372C (F458L) missense mutation and a 1668 ACAG 1669 splice site mutation. |
| TextSentencer_T6 |
724-917 |
Sentence |
denotes |
After initial treatment with intravenous glucose and carnitine, the patient has thrived on a low-fat diet supplemented with medium-chain triglyceride oil and carnitine and avoidance of fasting. |
| T6 |
724-917 |
Sentence |
denotes |
After initial treatment with intravenous glucose and carnitine, the patient has thrived on a low-fat diet supplemented with medium-chain triglyceride oil and carnitine and avoidance of fasting. |
| TextSentencer_T7 |
918-1036 |
Sentence |
denotes |
Her ventricular hypertrophy resolved significantly over 1 year, and cognitively, she is in the superior range for age. |
| T7 |
918-1036 |
Sentence |
denotes |
Her ventricular hypertrophy resolved significantly over 1 year, and cognitively, she is in the superior range for age. |
| TextSentencer_T8 |
1037-1176 |
Sentence |
denotes |
Clinical recognition of VLCAD deficiency is important because it is one of the few directly treatable causes of cardiomyopathy in children. |
| T8 |
1037-1176 |
Sentence |
denotes |
Clinical recognition of VLCAD deficiency is important because it is one of the few directly treatable causes of cardiomyopathy in children. |